Barclays maintains an 'Overweight' on Tim Hortons (THI); Q1 Preview: Compelling Defensive Earnings Growth Story
Get Alerts THI Hot Sheet
Price: $85.92 --0%
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Tim Hortons (NYSE: THI) price target of CAD$56.00.
Analyst, Jim Durran, said, "Forecasting Q1 EPS of $0.59 (+23% y/y) vs. consensus of $0.58. Forecast revenue growth of 9.8% y/y expected to be driven by 5.5% CSS in Canada and 6.0% in the U.S. EBITDA is expected to be up 13.5% to 169mn. We expect Tim's continued share buy-back activity to drive EPS growth of 8% y/y, or 37% of total EPS growth in Q1."
For an analyst ratings summary and ratings history on Tim Hortons click here. For more ratings news on Tim Hortons click here.
Shares of Tim Hortons closed at $57.36 yesterday.
Analyst, Jim Durran, said, "Forecasting Q1 EPS of $0.59 (+23% y/y) vs. consensus of $0.58. Forecast revenue growth of 9.8% y/y expected to be driven by 5.5% CSS in Canada and 6.0% in the U.S. EBITDA is expected to be up 13.5% to 169mn. We expect Tim's continued share buy-back activity to drive EPS growth of 8% y/y, or 37% of total EPS growth in Q1."
For an analyst ratings summary and ratings history on Tim Hortons click here. For more ratings news on Tim Hortons click here.
Shares of Tim Hortons closed at $57.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Vivos Therapeutics posts 35% revenue gain but widens net loss
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Barclays, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share